Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa....

Despite back-to-back phase 3 trial wins in atopic dermatitis, Incyte’s ruxolitinib cream isn’t immune to class-wide JAK inhibitor safety scrutiny.&nbs...

Bayer, currently in the midst of a gung-ho cell therapy expansion in the U.S., is turning its attention back to Europe as it looks to beef up its birth control manuf...

When Eli Lilly last month revealed that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing facility in Branchburg, New Jersey, the drugmak...

Biogen and partner Eisai's aducanumab have won a landmark—yet widely criticized—FDA approval for Alzheimer's disease drug Aduhelm, and the companies are eying a...

Actor Molly Ringwald is famous for the movie "16 Candles," but these days she’s more concerned about The 16 Vaccine project with Sanofi. Ringwald, who is mom to a ...

As more cell, gene and immunotherapy applications emerge for lentiviral vectors, demand for their production continues to rise. With its move last week into a larg...

The pandemic colored most opinions last year—including patient opinions about pharma. Cancer patients, often sidelined at home during the crisis, were paying particu...

Since the onset of the coronavirus pandemic, Jubilant HollisterStier has been busy churning out COVID-19 treatments and more recently vaccines. Now it's turning...

The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. The FDA’s approval on Monday is set to cause a ripple effect ...